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Background: Several studies have investigated the association between coffee consumption 
and cardiovascular disease, but little is known about c ffee intake and risk of venous 
thromboembolism (VTE). 
Objective: The aim of this prospective cohort study was to investigate the association 
between coffee consumption and risk of incident VTE in a general population. 
Methods: Information about coffee consumption habits was obtained by a self-administered 
questionnaire in 26 755 subjects, aged 25-97 years, who participated in the fourth survey of 
the Tromsø study (1994-95). Incident VTE events were r gistered until the end of follow-up, 
1 September 2007.  
Results: There were 462 incident VTE events (1.60 per 1000 person-years, 95% CI: 1.46-
1.75) during a median of 12.5 years of follow-up. A daily consumption of 3-4 cups was 
borderline associated (HR: 0.70; 95% CI: 0.48-1.02), while 5-6 cups (HR: 0.67; 95% CI: 
0.45-0.97) of coffee was significantly associated with reduced risk of VTE compared to 
coffee abstainers in multivariable analysis adjusted for age, sex, BMI, smoking status, 
physical activity, diabetes, history of cardiovascular disease and cancer. Similar risk estimates 
were found for provoked and unprovoked VTE, and in sex-stratified analyses. 
Conclusion: Our findings suggest a possible U-shaped relation between coffee consumption 
and VTE, and that moderate coffee consumption may be associated with reduced risk of VTE. 
However, more studies are needed to establish whether a moderate coffee consumption is 
inversely associated with the risk of VTE. 
 




Venous thromboembolism (VTE), consisting of deep venous thrombosis (DVT) and 
pulmonary embolism (PE), is a disease with serious short- and long-term complications, such 
as post-thrombotic syndrome, pulmonary hypertension, and potential fatal outcome (1, 2). The 
annual incidence of VTE is 1-2 per 1000 person-years in developed countries (1, 3, 4), and it 
is the leading cause of preventable in-hospital deaths in the US (2). VTE is a multicausal 
disease of which the incidence increases markedly with age (1, 4, 5). Despite numerous 
known risk factors, still 25-50% of the events occur in the absence of predisposing factors (2, 
6). In contrast to arterial cardiovascular disease (e.g. myocardial infarction), the incidence of 
VTE has not declined during the last decades (1). The relation between lifestyle factors and 
arterial cardiovascular disease has been extensively examined, while limited knowledge exists 
on the association between lifestyle factors and risk of VTE. 
 
Coffee is one of the most widely consumed beverages in the world, and has been associated 
with both health benefits and health risks (7). Epidemiological studies have reported diverging 
results regarding the association between coffee consumption and risk of CVD (8-11), but 
more recent cohorts have shown an inverse association (8-11).   Recently, a J-shaped curve 
was suggested for the association between coffee intake and acute coronary syndrome (ACS) 
(12), where a moderate coffee consumption was associated with reduced risk of ACS. 
 
To our knowledge, only one prospective cohort study, including older women only, has 
investigated the association between coffee consumption and venous thrombosis (13). This 
study reported a weak inverse association between coffee consumption and VTE, but the 
association disappeared after adjustments for body mass index (BMI) and diabetes (13). Thus, 
our current knowledge of the impact of coffee consumption on risk of VTE is limited. The 
aim of the present study was to explore the associati n between coffee consumption and the 
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risk of future VTE, and to test whether this relation was linear, in a large prospective cohort 




Subjects were recruited from the fourth Tromsø study, a single-centered, prospective, 
population-based health study, which was carried out in 1994-95. All inhabitants of the 
municipality of Tromsø, aged 25 or older, were invited to participate, and 77% of the eligible 
population (n= 27 158) participated. The study was approved by the regional committee of 
research ethics, and all subjects gave their written consent to participate. Participants were 
excluded due to the following reasons; 300 did not give their consent to medical research, 43 
were not officially registered as inhabitants of the municipality of Tromsø at the date of 
enrolment, 47 had a known history of VTE, and 13 had missing values on coffee 
consumption. Thus, a total of 26 755 participants were included in the study, and were 
followed from the date of enrolment in 1994-95 until the end of follow-up, 1 September 2007. 
 
Baseline measurements 
Baseline information was collected by physical examination, blood samples and self-
administered questionnaires at a single time-point (date of inclusion). Height and weight were 
measured with subjects wearing light clothes and no shoes. BMI was calculated as weight in 
kilograms divided by the square of height in meters (kg m-2). Non-fasting blood samples were 
collected from an antecubital vein, serum was prepared by centrifugation after 1 h respite at 
room temperature, and further analyzed at the Department of Clinical Chemistry, University 
Hospital of North Norway. Serum total cholesterol was analyzed by the CHOD-PAP method 
(Boeringer Mannheim, Mannheim, Germany). Baseline information on coffee consumption, 
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diabetes, smoking status, prior CVD (myocardial infarction, angina pectoris and stroke), daily 
caloric intake, physical activity, and current hormne therapy was collected by a self-
administered questionnaire. The coffee consumption questions were: “How many cups of 
boiled coffee (coarsely ground coffee for brewing) do you usually drink daily?” and “How 
many cups of coffee, other than boiled, do you usually drink daily?”  Physical activity was 
defined as exercise with sweat production and breathl ssness ≥1 hour per week during leisure 
time. Current hormone therapy was defined as current use of oral contraceptives or current 
use of estrogen supplementation (tablets or patches). Information on cancer was obtained 
from the Norwegian Cancer Registry, and cancer exposure was defined as all diagnoses of 
cancer within the last 10 years prior to the baseline inclusion date. Data on daily caloric intake 
was available for a subpopulation of participants aged<70 years (n=17 141), and was 
calculated from information on dietary habits given in the questionnaire (14). 
 
Identification and validation of venous thromboembolism 
All incident VTE events during follow-up (from date of examination in 1994-95 until 1 
September 2007) were identified by searching the hospital discharge diagnosis registry, the 
autopsy registry and the radiology procedure registry at the University hospital of North 
Norway as previously described (5). The University hospital of North Norway is the only 
hospital in the region, and all hospital care and diagnostic radiology is provided exclusively 
by this hospital.  
 
The medical records for each potential VTE case were r viewed by trained personnel, who 
were blinded to all the baseline variables, including coffee consumption habits. Unclear cases 
or disputes were resolved by discussion with a senior consultant expert on VTE diagnosis 
(JBH). For subjects derived from the hospital discharge diagnosis registry and the radiology 
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procedure registry, an episode of VTE was verified an recorded as a validated outcome when 
all four of the following criteria were fulfilled; (i) objectively confirmed by diagnostic 
procedures (compression ultrasonography, venography, s iral computed tomography (spiral-
CT), perfusion-ventilation scan (required moderate and high probability of PE), pulmonary 
angiography or autopsy); (ii) the medical record inicated that a physician had made a 
diagnosis of DVT or PE; (iii) signs and symptoms consistent with DVT or PE were present; 
(iv) the patient underwent therapy with anticoagulants (heparin, warfarin or a similar agent), 
thrombolytic therapy or surgery unless contraindications to anticoagulant treatment were 
specified in the medical record. Isolated calf vein DVT was diagnosed by compression 
ultrasonography alone or accompanied by venography if insecurity about the diagnosis and/or 
inadequate technical conditions (e.g. obesity).  For subjects derived from the autopsy registry, 
a VTE event was recorded as an outcome when the autopsy registry indicated VTE as cause 
of death or as a significant condition contributing to death. 
 
A VTE event was classified as provoked (≥1 provoking factors) or unprovoked (no provoking 
factors), by the presence of provoking factors at the time of diagnosis. Provoking factors 
were: recent surgery or trauma within the previous 8 weeks, acute medical conditions (acute 
MI, ischemic stroke or major infectious disease), active cancer, marked immobilization (bed 
rest >3 days, wheelchair, or long distant travels exce ding 4 hours within the last 14 days 
prior to event) or other provoking factors specifically described by a physician in the medical 
record (e.g. intravascular catheter).  
 
Statistical analyses 
For each participant, person-years were accrued from the date of enrolment in the Tromsø 
study (1994-95), to the date of the first VTE event, the date the participant died or moved 
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from the municipality of Tromsø, or to the end of fllow-up, 1 September 2007. Subjects who 
moved from the municipality of Tromsø (n=3 716) or died (n=3 000) during the study period 
were censored. 
 
Statistical analyses were performed using STATA version 11.0 (Stata corporation, College 
station, Texas, USA). The distribution of baseline characteristics was adjusted for age (with 
crude standard deviations), and tests for linear trends were carried out using logistic and linear 
regression. Age- and sex-adjusted incidence rates wi h 95% confidence intervals (CI) were 
calculated by direct standardization as number of events per 1000 person-years using the age 
distribution of the whole cohort as standard population. The association between daily coffee 
consumption and the risk of total, provoked and unprovoked VTE was assessed using Cox 
proportional hazard regression models to estimate age and sex-adjusted, and multivariable 
adjusted hazard ratios (HR) for VTE with 95% CI. The two questionnaire variables on coffee 
consumption (by type of coffee) were combined into a daily coffee consumption variable, 
which was used as our main exposure variable divided into 5 categories: 0 cups/day, 1-2 
cups/day, 3-4 cups/day, 5-6 cups/day and more than 6 cups daily. The coffee abstainers (0 
cups/day) served as the reference group. To correct for potential confounding, other risk 
factors and concomitant diseases possibly related to both coffee consumption and venous 
thrombosis were included in a multivariable model. Hence, in the multivariable analyses, the 
HRs were adjusted for age, sex, BMI, smoking status (c rrent smoker yes/no), physical 
activity, prior history of CVD, cancer and self-reported diabetes. Adjustments for daily caloric 
intake in addition to the abovementioned factors were performed in a model including a 
subgroup of participants <70 years only. Further adjustments for estrogen use (as a 3-level 
variable; men, women not on estrogens, women on estrogens) were also conducted. Statistical 
interactions of coffee consumption with age or sex w re tested by including cross product 
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terms in the proportional hazard models. There were no statistical interactions between coffee 
consumption and age or sex. The proportional hazard assumption was verified by evaluating 
the parallelism between the curves of the log-log survival function for categories of total 
coffee consumption. In addition, a test of the propo tional hazard assumption using 
Schoenfeld residuals was performed for all of the rel vant variables. 
 
RESULTS 
Table 1 shows the characteristics of VTE-patients at he time of the event. In total, there were 
462 validated incident VTE events during 289 338 person-years of follow-up (median follow-
up time 12.5 years). The overall crude incidence rat  was 1.60 per 1000 person-years (95% 
CI: 1.46-1.75). Of the events, 64.3% (n=297) were DVT, while the remaining 35.7% (n=165) 
were pulmonary embolism with or without concurrent DVT (table 1). Moreover, 41.8% 
(n=193) of the events were classified as unprovoked. Active cancer was the most common 
provoking factor for VTE. The proportions of DVT and PE, provoked and unprovoked VTE, 
and the presence of clinical risk factors and provoking factors did not differ between sexes 
(data not shown). 
 
Distribution of age-adjusted characteristics of subjects across categories of daily coffee 
consumption at baseline is shown in table 2. Age, BMI and total cholesterol levels increased 
significantly across categories of higher coffee consumption. The proportion of men and 
smokers increased, while the degree of physical activity and current use of hormone therapy 
(women only) decreased with increasing coffee consumption. 
 
Incidence rates and hazard ratios for total, provoked and unprovoked VTE across categories 
of increasing coffee consumption are presented in table 3. The age- and sex-adjusted 
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incidence rate was highest among the coffee abstainers (IR=2.14 per 1000 person-years; 95% 
CI: 1.54-2.96). A moderate coffee consumption was inversely associated with risk of VTE 
(table 3). Drinking 3-4 cups (HR: 0.70, 95% CI: 0.48-1.02) was borderline associated, while  
5-6 cups (HR: 0.67, 95% CI: 0.45-0.97) daily was signif cantly associated with reduced risk 
of VTE compared to coffee abstainers in analyses adjusted for age, sex, BMI, smoking status, 
physical activity, cancer, prior CVD and diabetes. The inverse association of coffee 
consumption was attenuated for subjects drinking more than 6 cups of coffee daily 
(multivariable HR: 0.85; 95% CI: 0.58-1.24). Similar risk estimates were found for provoked 
and unprovoked VTE in separate analyses (table 3). Including daily caloric intake in addition 
to the other adjustments among participants <70 years, did not significantly change the risk 
estimates (table 3). Further adjustments for current hormone therapy did neither significantly 
alter the risk of VTE (data not shown). The inverse a sociation between moderate coffee 
intake and risk of VTE was similar in men and women in sex-stratified analysis (data not 




Our findings indicate that a moderate coffee consumption may be inversely associated with 
risk of VTE. A daily coffee consumption of 5-6 cups was significantly associated with 33% 
reduced risk of VTE compared to those who abstained from coffee. For heavy coffee drinkers 
(>6 cups daily) the inverse association of moderate coffee consumption was weakened. 
Similar risk estimates were found in separate analyses of unprovoked and provoked VTE, and 
in sex-stratified analyses. These findings suggest a possible U-shaped association between 
coffee intake and VTE. 
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To the best of our knowledge, only one previous observational study has investigated the 
association between coffee intake and VTE. In the Iowa Women’s Health study, 37 393 
women aged 55-69 years were included and followed for a median of 13 years (13). In 
agreement with our findings, this study reported a we k inverse association between coffee 
consumption and risk of VTE in a multivariable model adjusted for age, kilojoules, education 
level, smoking status and physical activity (13). However, the association vanished after 
further adjustments for BMI and diabetes (13). In our study, both men and women within a 
wide age-range were included, and the inverse association of moderate coffee consumption 
(5-6 cups daily) and VTE remained significant after multivariable adjustments.  
 
In contrast to the limited number of studies on coffee and VTE, the relationship between 
coffee consumption and arterial CVD has been extensiv ly examined. Several prospective 
cohort studies have shown an inverse association between CVD and coffee. The Stockholm 
Heart Epidemiology program (10), the Iowa Women’s Health Study (8) and a pooled analysis 
of data from the Health Professionals Follow-up Study and the Nurses’ Health Study (9) 
found a modest beneficial effect of coffee consumption on the risk of CVD mortality and 
overall mortality. Similar findings were reported in a Finnish cohort study (11). Contrary, 
early cohort studies did not find any association between coffee consumption and CVD (15-
17), whereas some case-control studies even showed a positive association between coffee 
and risk of nonfatal myocardial infarction (18-20). 
 
The high contents of polyphenols (especially flavanoids and phenolic acids) in coffee may 
explain the inverse association between coffee consumption and the risk of VTE (21). Platelet 
aggregation is vital for the formation of both arterial and venous thrombi (22, 23). Dietary 
polyphenols inhibit platelet aggregation (22, 24), and intake of 200 ml coffee has been shown 
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to inhibit platelet aggregation in humans ex vivo (24). The platelet inhibiting effect was 
independent of caffeine (24). In contrast, platelet reactivity was stimulated by caffeine 
administered in quantities corresponding to one cup of coffee (25). Thus, inhibition of platelet 
reactivity by coffee intake may reflect that the plate et inhibiting effect of polyphenols is 
superior to the platelet stimulating effect of caffeine, and thus may contribute to the protective 
effect of moderate coffee consumption on VTE risk. 
 
Even though limited data are available, experimental studies suggest that coffee consumption 
increases the fibrinolytic activity without affecting the coagulation system. Coffee ingestion 
has been found to shorten whole blood fibrinolysis time, an effect ascribed to caffeine (26). 
Supportive results were found in another study where caffeine exposure in humans increased 
tissue plasminogen activator (t-PA) activity and decreased plasminogen activator inhibitor 
(PAI) levels in plasma (27). In contrast, a study comparing the intake of decaffeinated coffee 
with caffeinated coffee among 20 human subjects, found no differences in fibrinogen levels, 
platelet adhesiveness or clot lysis time (28). In addition, two randomized studies comparing 
filtered and boiled coffee with no coffee (29), reported no differences in hemostatic variables 
such as fibrinogen, factor VII activity, factor VIII antigen, protein C and protein S during the 
coffee intervention (29).  
 
Confounding is a potential problem of cohort studies due to their non-randomized nature. 
Possible presence of personal characteristics that make the coffee abstainers different from the 
coffee consumers, may give rise to an observed inverse association between coffee 
consumption and risk of VTE that is actually a result of unrecognized confounders, rather 
than a true association. Coffee consumption is often perceived as part of an unhealthy lifestyle 
(30), and when confronted with health issues, some abstain from coffee for the benefit of 
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health (30). Thus, the high incidence of VTE among coffee abstainers in our study could 
possibly be explained by underlying disease(s). However, the incidence of self-reported 
diabetes mellitus, cardiovascular diseases, and cardiovascular risk factors such as smoking, 
and serum lipids were not increased in coffee abstainers in our study. This argument, along 
with our finding that moderate coffee consumption te ded to reduce the risk of unprovoked 
VTE, attenuated the hypothesis that underlying diseases are confounders for the beneficial 
impact of coffee consumption on VTE risk. 
 
The main strengths of our study are its prospective design, the large number of participants 
recruited from a general population with a high attendance rate, long follow-up time and 
validated VTE events. One single hospital serves th entire Tromsø population, which 
enhances the possibility of a complete VTE registry. The study also has limitations. 
Unfortunately, we did not have verified baseline information on previous history of VTE 
among the study-subjects. Hence, some of the subjects who were treated as healthy 
participants during follow-up could be prevalent VTE-cases who should have been excluded 
from the study population. However, this would lead to only a small change in the overall 
number of person-years at risk, and thus would presumably have a negligible influence on the 
risk estimates. Certain data points, such as the circumstances at the time of VTE diagnosis 
(e.g. provoking factors), were collected retrospectiv ly, thus the potential of ascertainment 
bias in some cases cannot be completely ruled out. Lifestyle habits such as coffee 
consumption are highly modifiable. A possible change in risk profile during follow-up may 
lead to misclassification bias which attenuates the real association (31). Another possible 
study limitation is self-reported information. However, self-reported coffee consumption has 
been demonstrated to have high validity (32, 33) and reproducibility over time (34, 35). 
Information on daily caloric intake was not available for all subjects. However, adjustments 
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for daily caloric intake among a subgroup of participants aged 25-69 years did not alter the 
risk estimates. Finally, we were not able to investigate the contribution of caffeine 
independently because the questionnaire did not include questions about decaffeinated coffee. 
 
In conclusion, our findings suggest a possible U-shaped relationship between coffee 
consumption and VTE, and that moderate coffee consumption may be associated with 
reduced risk of VTE in the general population. More studies from other general population 
cohorts are needed to ascertain whether dietary habits such as coffee consumption is 
associated with the risk of VTE. 
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Table 1. Characteristics of the incident VTE events (n=462) during follow-up. The Tromsø 
study 1994/95-2007. 
 % (n) 
Men 47.4 (219) 
Deep vein thrombosis 64.3 (297) 
Pulmonary embolism 35.7 (165) 
Unprovoked  41.8 (193) 
Clinical risk factors - 
Estrogen*  14.4 (35) 
Pregnancy/puerperium*  1.2 (3) 
Heredity† 2.8 (13) 
Other medical conditions‡ 21.6 (100) 
Provoking factors - 
Surgery 17.1 (79) 
Trauma 6.7 (31) 
Acute medical conditions 15.1 (70) 
Cancer 22.9 (106) 
Immobility§ 19.0 (88) 
Other¶ 4.1 (19) 
* Only women included in analysis  
† VTE in first degree relative before aged 60 years. 
‡ Includes other diseases within the previous year (myocardial infarction, ischemic stroke, 
heart failure, inflammatory bowel disease, chronic i fections, chronic obstructive pulmonary 
disease, or myeloproliferative disorders). 
§ Immobility includes bed rest>3days, longtime travels with car, boat, train or by air >4 hours 
within last 14 days, or other type of immobilization. 
¶ Other provoking factor described by a physician in the medical record (e.g. intravascular 
catheter). 
Enga et al.                    Coffee consumption and VTE 
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Table 2. Baseline characteristics across categories of coffee consumption*. The Tromsø Study 1994/95-2007. 
Characteristics 0 cups/day 1-2 cups/day 3-4 cups/day 5-6 cups/day >6 cups/day P for trend 
Number of subjects 2671 2873 6581 7178 7452 - 
Number of events 36 51 126 118 131 - 
Men (%) 39.6 (1059) 39.4 (1133) 41.7 (2742) 47.0 (3372) 59.2 (4411) <0.001 
Age (years) 38.5±14.3 46.9±17.1 49.7±16.2 48.3±14.5 46.0±12.6 <0.001 
BMI (kg/m2) 25.2±4.1 24.9±3.8 25.0±3.8 25.2±3.8 25.4±3.8 <0.001 
Total cholesterol (mmol/l) 5.75±1.20 5.85±1.30 5.99±1.35 6.09±1.29 6.25±1.27 <0.001 
Self-reported diabetes (%) 1.1 (30) 1.3 (69) 1.0 (137) 1.2 (140) 1.0 (103) 0.50 
Self-reported prior CVD† (%) 2.8 (103) 2.8 (223) 2.6 (535) 2.9 (509) 3.1 (404) 0.06 
Current smoking (%) 15.6 (494) 16.0 (476) 24.2 (1560) 39.3 (2790) 58.0 (4341) <0.001 
Hormone therapy (%) ‡ 23.7 (271) 23.9 (265) 20.8 (480) 18.3 (449) 14.9 (299) <0.001 
Physical activity (%) 30.0 (1005) 31.1 (937) 30.5 (1955) 28.9 (2077) 26.4 (2083) <0.001 
Cancer (%) 1.3 (37) 1.4 (74) 1.2 (160) 1.3 (163) 1.3 ( 29) 0.91 
Daily caloric intake§ 1775±513 1803±496 1843±512 1890±516 1997±553 <0.001 
* Values are given as age-adjusted means ± crude standard deviations or as age-adjusted percentages with absolute numbers in brackets. 
† Includes history of myocardial infarction, angina pectoris or stroke. 
‡ The percentages are based on the female population. 
§ Based on a subpopulation of participants <70 years (n=17 141).
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Table 3. Incidence rates (IR) and hazard ratios (HR) for VTE by categories of daily coffee consumption. The Tromsø study 1994/95-2007. 
 Person  
years 




Total VTE  - - - - - - 
0 cups/day 27298 36 2.14 (1.54-2.96) Ref Ref - 
1-2 cups/day 29808 51 1.59 (1.21-2.09) 0.77 (0.50-118) 0.78 (0.51-1.21) - 
3-4 cups/day 70435 126 1.51 (1.27-1.80) 0.70 (0.48-1.02) 0.70 (0.48-1.02) - 
5-6 cups/day 79014 118 1.40 (1.17-1.68) 0.68 (0.47-0.99) 0.67 (0.45-0.97) - 
>6 cups/day 82783 131 1.74 (1.46-2.06) 0.88 (0.61-099) 0.85 (0.58-1.24) - 
P for trend - - - 0.96 0.71 - 
Provoked VTE - - - - - - 
0 cups/day 27199 21 1.21 (0.79-1.85) Ref Ref - 
1-2 cups/day 29646 25 0.78 (0.53-1.15) 0.62 (0.35-112) 0.61 (0.34-1.10) - 
3-4 cups/day 70102 76 0.88 (0.70-1.10) 0.70 (0.43-1.14) 0.67 (0.41-1.09) - 
5-6 cups/day 78635 68 0.81 (0.64-1.03) 0.66 (0.40-1.08) 0.62 (0.38-1.01) - 
>6 cups/day 82401 79 1.05 (0.84-1.31) 0.92 (0.57-1.49) 0.84 (0.51-1.38) - 
P for trend - - - 0.50 0.84 - 
Unprovoked VTE - - - - - - 
0 cups/day 27190 15 0.95 (0.57-1.57) Ref Ref - 
1-2 cups/day 29622 26 0.86 (0.58-1.26) 0.98 (0.52-186) 1.06 (0.55-2.04) - 
3-4 cups/day 69936 50 0.65 (0.49-0.85) 0.70 (0.39-1.25) 0.75 (0.41-1.36) - 
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5-6 cups/day 78539 50 0.61 (0.46-0.80) 0.71 (0.40-1.26) 0.74 (0.1-1.35) - 
>6 cups/day 82193 52 0.70 (0.53-0.92) 0.84 (0.47-1.9) 0.85 (0.46-1.56) - 
P for trend - - - 0.49 0.42 - 
Total VTE ¶ - - - - - - 
0 cups/day 26155 29 2.03 (1.41-2.92) Ref Ref Ref 
1-2 cups/day 26548 27 1.30 (0.89-1.89) 0.60 (0.35-102) 0.64 (0.37-1.08) 0.57 (0.29-1.14) 
3-4 cups/day 61766 77 1.35 (1.08-1.69) 0.61 (0.39-093) 0.65 (0.42-1.00) 0.50 (0.28-0.89) 
5-6 cups/day 72912 78 1.18 (0.95-1.47) 0.53 (0.34-081) 0.56 (0.36-0.87) 0.60 (0.35-1.05) 
>6 cups/day 79723 113 1.56 (1.29-1.87) 0.77 (0.51-116) 0.78 (0.51-1.20) 0.89 (0.52-1.52) 
P for trend - - - 0.88 0.74 0.33 
* Incidence rate per 1000 person years. 
† Adjusted for age and sex, with 95% confidence intervals 
‡ Adjusted for age, sex, BMI, smoking status, physical activity, diabetes, history of CVD and cancer, with 95% confidence intervals. 
§ Adjusted for age, sex, BMI, smoking status, physical activity, diabetes, history of CVD, cancer and daily caloric intake, with 95% confidence 
intervals. Includes only participants <70 years. 
¶ Includes a subpopulation of participants <70 years (n=17 141). 
